PDL BioPharma News

PDL BioPharma, Inc. today announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company under PDL's Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules.

PDL BioPharma Inc. said Monday that Eli Lilly & Co. is licensing its drug candidate teplizumab, an experimental treatment for newly diagnosed type 1 diabetes.

Last weeka s top five guru bargain stocks were Palm Inc, PDL BioPharma Inc, KB Home, AirTran Holdings Inc, and Owens & Minor Inc.

Biotechnology company PDL BioPharma Inc. said Wednesday it will pay shareholders a special dividend of $1.67 per share.

PDL BioPharma, Inc. today announced that it has established the per share amount of the previously announced $200 million special dividend as $1.67 per share.

PDL BioPharma Inc. filed Quarterly Report for the period ended 2009-09-30. Protein Design Labs Inc.

The Denmark-based owner of a biotech factory in Brooklyn Park announced Thursday it plans to close the plant, eliminate about 130 jobs there and attempt to sell the high-tech facility it bought less than two years ago.

PDL BioPharma Inc., which promised significant returns to shareholders since adopting an unusual royalty-collecting business model following last year's spinoff of its R&D division, has opted to monetize a percentage of its antibody royalties from Genentech Inc.

In May Cougar Biotechnology Inc., a six-year-old company developing treatments for prostate cancer, was acquired by Johnson & Johnson for roughly $1 billion.

Recently, Seth Klarman's hedge fund filed a flurry of 13G's and we're back again as always to track the latest developments out of Baupost Group.

Recently, Seth Klarman's hedge fund filed a flurry of 13G's and we're back again as always to track the latest developments out of Baupost Group.

Selick has served as chief executive officer of Threshold Pharmaceuticals since June 2002.

The company currently receives royalties from the respiratory virus drug Synagis, developed by MedImmune, but there is an ongoing dispute over patents.

PDL BioPharma, Inc. today announced that the company will hold a conference call and webcast on Thursday, July 30 at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter of 2009 and provide a business update.

In the May issue of Portfolio Manager's Review - " The Superinvestor Issue ," our team highlighted 100 companies owned by well respected investors and profiled 30 of them.